

Promoting Access to TB Products GDF's 2024 Updates


Dr Magali Babaley

Strategic Procurement and Business Intelligence Manager, StopTB-GDF 2024 Joint UNICEF, UNFPA, and WHO Meeting, Copenhagen, 2 – 6 December 2024

hosted by **₩UN**OPS →



StopTB partnership and the Global Drug Facility (GDF)



- GDF was established in 2001
- Part of the United Nations (hosted by the United Nations Office for Project Services - UNOPS)
- Enterprise within the Stop TB Partnership
- Largely funded by USAID



• GDF is ISO 9001:2015 certified



End-to-end approach along entire product lifecycle, coordinating TB market stakeholders

One-stop shop for TB products

All TB programmes are eligible to procure from GDF regardless of income classification or funding source in alignment with national rules and regulations (165 countries served since its inception in https://www.stoptb.org/facilitate-access-to-tb-drugs-diagnostics/global-drug-facility-gdf



 \rightarrow



GDF Mission and Strategic Framework, 2023-2028

MISSION	Worldwide, equitable access to TB products							
VISION	Sustainable, viable affordable TB prod	e global markets that delive lucts	r innovative, quality-a	ssured,				
STRATEGIC OBJECTIVES	1 Drive stewardship of global TB markets	 Demonstrate best in class model for global sourcing and supply 	Facilitate country- led procurement and supply solutions	(4) Incentivize and introduce innovations				
OPERATIONAL PRINCIPLES	End-to-end product life-cycle management	Integrated procurement services maximizing efficiency & automation	Tailored solutions to address TB market challenges	Cost-effective, greener supply chains				

https://www.stoptb.org/2023-2028-operational-strategy

 \rightarrow



GDF Expansion into Antimicrobial Resistance (AMR)

- Strategic review revealed AMR to be an area where GDF could add value and have significant impact.
 - An expansion into medicines for AMR was then included as part of GDF's new 2023-2028 Strategy
- GDF to supply some AMR medicines when there is a value-add to leverage the GDF platform
- Progress to date:
 - May 2024, signed a partnership agreement with the Global Antibiotic Research & Development Partnership (GARDP) to support the introduction of new, priority antibiotics for AMR
 - GARDP is an AMR-focused product development partnership working with 70 partners across 16 countries to accelerate the development and access to treatments for drug-resistant infections. <u>https://gardp.org</u>


o June 2024, Co-hosted with WHO, GARDP, and Unitaid the SECURE Operational Planning meeting

• <u>Next steps</u>: collaborate with partners to determine which medicines to include in a GDF AMR catalog, and support product road maps for introduction and scale-up in countries

https://www.stoptb.org/news/new-partnership-improve-access-new-antibiotics-low-and-middle-income-countries-boost-efforts








hosted by

WUNOPS

-





hosted by

WUNOPS

 \rightarrow



2024 New Products Introduction

Ultraportable Digital X-ray







(with safety accessories) (10 Product Code: 200

FDR Xair i

X-ray Sy

exposi

usec

FDR Xair Kit

- 2024 GDF tender led to price decreases up to 67% for ultraportable Digital Xray kits and services offered, leading to improved access and sustainable use
- Suppliers of CAD/AI software are encouraged to submit their dossier to the WHO PQ Program for assessment

https://www.who.int/news-room/articles-detail/call-for-expression-ofinterest-by-manufacturers-of-software-for-computer-aided-detection-oftuberculosis-(cad)-to-submit-products-for-who-expert-assessment

Product Code: 200030 PeakBeatle06P Kit is an Ultraporta

Peak Bea

(with safety ac

System fully battery-powered capable of 200 exposures with fully charged batteries that can be used for TB screening and various other indications.

Computer-Aided Detection based on Artificial Intelligence (CAD/AI) software

InferRead DR Chest Software Perpetual License (INDRCHESTPL) and 3 years License S&M (INDRCHEST3YL)

Product Code: 200001 and 200027

InferRead DR Chest Software is able to detect TB, for which it processes both antero-posterior (AP) and postero-anterior (PA) chest X-ray in less than 10 seconds. The output is a binary outcome for TB, continuous values for TB-probability and annotated images with rectangles indicating the areas identified to TB



QXR AI SOFTWARE

Perpetual License (qXRPERP) and 3 years License S&M (qXRLICEN)

Product Code: 200036 and 200037

qXR AI is able to detect TB, for which it processes both antero-posterior (AP) and postero-anterior (PA) chest X-ray in less than 10 seconds. The output is a score ranging from 0-1 shown together with a heatmap and translated into a pre-set binary (positive / negative) score.

hosted by WDPS



Newly Added to GDF Catalog: SIILTIBCY[™] skin test



Stop TB Partnership Global Drug Facility Info Sheet: SIILTIBCY https://www.stoptb.org/sites/default/files/documents/SIILTIBCY%20GDF%20Info%20Sheet.pdf

SIILTIBCY[™] skin test is classified as MEDICINE

hosted by

UNOPS

PRODUCT CODE	DESCRIPTION (PRODUCT, PACKAGING)	NUMBER OF UNITS PER PACK	PRICE OR PRICE RANGE (USD)	ORUSENSTUR TO DRUESSENT TO NECTON
rdESAT-6/rCFP- 10-0.5/0.5-(V)-1 (SIILTIBCY)	rdESAT-6/rCFP 0.5 μg/0.5 μg. Solution for injection intradermal, vial of 1ml. Each vial contains 10 doses/tests	1	15.00	Detection of Mtb infection




BREAKING NEWS: Only \$1.50 to Detect TB Infection With the Next-Generation SIILTIBCY Test

https://www.stoptb.org/news/breaking-news-only-150-detect-tb-infection-next-generation-siiltibcy-test



GDF Catalogues

GDF Medicines Catalog



hosted by

WUNOPS



Stop () Partnership GLOBAL DRUG FACILITY			GDF TB Diagnostics Ordering List April, 2023			Quantity	Product price Concessional priors for the wilgible exertises are found here: <u>Network index on the comparation in the comparation of the comparation of the comparation</u> the comparation contrast, these areas contrast, study of One in charge.		
Sarsted 🛩	Product Name	Pack si: 🛩	Minimum remainir ~ Shelf life	Product technical specifications	Suppli	to order Indic		Currenc	Total Cos
1. DETECTIO	N AND RESISTANCE OF MTB								
1.1 MOLECU	ILAR TESTING: POC / NEAR-POC								
1.1.1 Truena	t MTB equipment			-					
105689	Truetab Lino Die Workstation (623020001)	1 set			Molbio Diagnostics		10000.00	USD	ŝ
106690	Truetab Due Workstation (643010001)	1 set	N/A	Possiab Hoad Time Quantitative micro RCB splarem in run 22 - 25 samples / Bhavas. The workstation has Optical Hormscores, Them Workshop Mich a speed of Optics of RAQ25 minutes. Interface: We1 36, Blavester Wi1 Pin Sha Territor LD Dalays, The internet warming to 12 months how the data of installation. No.1 Treads and from Chartenities micro RCB Realing (EQ020201). Dial Mich Chartenities and Pin Realing (EQ020202). 0 No.1 Treads and FmT The Chartenities micro RCB Realing (EQ020202). 0 0 0 1 Treads and FmT The Chartenities micro RCB Realing (EQ020202). 0 0 0 1 Treads and FmT The Chartenities micro RCB Realing (EQ020202). 0 0 0 1 Treads and FmT The Chartenities micro RCB Realing (EQ020202). 0 0 0			14000.00	USD	s
106691	Truelab Quartize Workstation (653010001)	1 set	Totalda Ruat Time Quantitative micro RCI Systems to run 43 -45 samples / & hours. The workstation has Optics: Flacemanne, Three Wavelength with a quere of 40 Optice #PC/SCI minimum, Interface: WFA1, Sig. Blacesterk with Auto-calculations with a merged 202000 set microline Optication (setting merger and re-SCI). (Biologia Quantitative C ⁺ Touch Science ICD Dalays), The instrument warranty A 12 months from the date of insultation. 10. How the includes: 10. Microline includes:		Molbio Diagnostics		18000.00	USD	s

GDF Ordering List: help in planning and budgeting and contain detailed information on each available product

> 600 items

GDF Diagnostics, Medical Devices and other Health Products Catalog

All are available online! GDF Product Catalog | Stop TB Partnership



Drug Resistant -TB Regimen Price Reductions



As of 22/11/2024

hosted by

 \rightarrow




GDF Savings in 2024

GDF saved **US\$ 41 million** as of 30 September 2024 equivalent to the cost of treating an additional **94,250 adults** with DR-TB using the newly-recommended **BPaLM regimen** or treating an extra **4 million** people with **3HP for TB prevention** or test additional **1.12 million of people** for TB with GeneXpert MTB/RIF Ultra.

These savings are the results of GDF strategic procurement and collaboration with Donors (USAID and Global Fund)

hosted by

UNOPS




- GeneXpert XDR and MTB/RIF-Ultra Price Reduction
- 3HP Price Reduction
- DR-TB Medicines Price Reduction
- Downward Adjustment of Order Volumes to Avoid Waste / Flexibility to Cancel/ Postpone Orders and to Choose Freight Modes



GDF Strategic Rotating Stockpile

Benefits to suppliers must be passed to patients



hosted by

WUNOPS

Suppliers awarded as primary suppliers in GDF tenders are prioritized for inclusion in the GDF Strategic Rotating Stockpile






2024 GDF New Record - US\$ 367 Million of TB Products Procured

 \Rightarrow

UNOPS




www.stoptb.org



2024 GDF Top 10 TB-Selling Medicines (in volume)

Quantities (in tablets, capsules) procured by countries via GDF



www.stoptb.org • 14

hosted by

⇒



Become a GDF Supplier



ELIGIBILITY CRITERIA for TB MEDICINES SUPPLIERS

not eligible to be suppliers to StopTB/GDF

Please check that you match the below criteria to become an eligible supplier for StopTB/GDF procurement:

IN THIS SECTION Global Drug Facility's Annual TB Are you the manufacturer of a TB medicine(s)? Please note that wholesalers or resellers of medicines are Medicines Suppliers Meeting, 2022

Archived procurement notices

- Do you produce a TB medicine(s) that are in the current StopTB/GDF Medicines Catalog? Or do you Procurement Notices produce a WHO-recommended medicine/new formulation for TB treatment that is not yet listed in the StopTB/GDF catalog?
- Does your TB medicine(s) fully comply with StopTB/GDF's Quality Assurance policy?

If you have answered "yes" to the three eligibility criteria above, please contact StopTB/GDF at gdf@stoptb.org, to the attention of the Sourcing and QA team.

StopTB/GDF will then require you to provide a list of information and supporting documentation about the TB medicine(s) you offer

For TB Medicines

https://www.stoptb.org/what-we-do/facilitate-access-tb-drugs-diagnostics/globaldrug-facility-gdf/suppliers/how-become-stoptbgdf-supplier/medicines

For TB diagnostics, Medical devices and laboratory supplies

https://www.stoptb.org/what-we-do/facilitate-access-tb-drugsdiagnostics/global-drug-facility-gdf/suppliers/how-become-stoptbgdfsupplier/suppliers-tb-diagnostics-medical-devices-laborato



ELIGIBILITY CRITERIA for SUPPLIERS OF TB DIAGNOSTICS. MEDICAL DEVICES & LABORATORY SUPPLIES

For TB Diagnostics, Medical Devices & other health products: Please check that you match the below criteria to become an eligible supplier for StopTB/GDF procurement

- 1. Do you manufacture/supply a TB diagnostics, medical device or other health products recommended by the WHO Global TB Programme, or the Expert Review Panel for Diagnostics or approved by one of the founding members of the Global Harmonization Task Force Regulatory agency?
- 2. Do you manufacture/supply a TB diagnostics, medical device & or other health products listed in the current StopTB/GDF Diagnostics, Medical Devices and Other Health Products Catalog?

3. Does your TB diagnostic, medical device or other health product fully comply with StopTB/GDF's Quality Assurance policy?



GDF Quality Assurance (QA) Policy and GDF Quality Monitoring Program (QMP)

Only suppliers with TB products meeting the GDF quality assurance policy (QA) are eligible to become GDF suppliers



hosted by WUNOPS




QA Requirements for TB Products for GDF Procurement Eligibility

Category of TB products	QA requirements
TB medicines	 Prequalified by WHO PQ programme, OR Authorized for use by a Stringent Regulatory Authority (SRA), OR Recommended by the WHO-coordinated Expert Review Panel for medicines (ERP).
Medical devices, IVDs, Medical software	 Recommendation by the WHO Global TB Programme, OR Regulatory approval/marketing authorization by former GHTF/IMDRF founding member for applicable risk classification, OR Prequalified by WHO PQ programme, OR Recommended by the WHO-coordinated Expert Review Panel for Diagnostics (ERPD), AND Declaration of Conformity in accordance with IMDRF and/or ISO 17050, AND Compliance with the quality requirements/specifications against test methods set for them
General laboratory supplies	 Declaration of Conformity in accordance with IMDRF and/or ISO 17050, AND Compliance with the quality requirements/specifications against test methods set for them
New emergency products	 In the case of new products where no other quality-assured products exist, GDF may accept products approved under Emergency Use Listing by WHO or SRA



GDF's Digital Transformation for Strategic Procurement



hosted by

UNOPS

 \Rightarrow

Suppliers are required to submit information about TB medicines to the CDP Portal for review and approval by the GDF

II Date Created	11 Formulation	II GDF Generic Code	n Dosage Form	II Primary Packaging Type	Number of units per FPP primary packaging type	Number of units per FPP secondary packaging type	11 Date Modified	n Supplier Name	Approval Status
10/07/2023	Single	<u>Bdq-100-(L/B)</u>	Uncoated tablet(s)	Blister(s)	10	100	20/11/2024		Approved
22/02/2023	Single	Pa-200-(L/B)	Uncoated tablet(s)	Blister(s)	10	100	20/11/2024		Approved
09/09/2020	Single	<u>Cs-250-(B)</u>	Capsule(s)	Blister(s)	10	100	18/10/2024		Approved
09/09/2020	Single	Cfz-100-(L/B)	Capsule(s)	HDPE container(s)	100	100	18/10/2024		Approved
21/06/2022	2FDC	3-HP-300/300-(8)	Film coated tablet(s)	Strip(s)	12	36	18/10/2024		Approved

» FPP Registration Status

Sourcing •

» FPP In Market

FPP In Market View

FPP Registration Status

Show 10 • entries Search:									
Date Created	II GDF Generic Code	Number of Units Per FPP Secondary Packaging Type	Country of Registration	FPP ¹¹ Registration Status	FPP ¹¹ Registration Date	FPP ^{II} Registration Expiry Date	11 Date Modified	II Supplier name	1 Approval Status
15/03/2023	2-FDC/RH-150/75-(B)	336	Mozambique	Registered	08/12/2022	08/12/2027	15/03/2023		Approved
13/07/2022	2-FDC/RH-150/75-(B)	336	Uzbekistan	Registered	29/06/2022	29/06/2027	15/02/2023		Approved
21/07/2021	2-FDC/RH-150/75-(B)	672	Turkmenistan	Registered	27/02/2022	27/02/2027	15/02/2023		Approved



TB Medicines Gaps

hosted by

WUNOPS

 \rightarrow

As of 21/11/2024

TB Medicines for Which Additional Suppliers are Required

Product Type	INN/strength/form
Adult DR-TB	Pretomanid 200mg tablets Delamanid 50mg tablets Clofazimine 100mg tablets functionally scored
Pediatric DR-TB	Bedaquiline 20mg tablets or dispersible tablets (preferably scored) Clofazimine 50mg tablets or dispersible tablets Cycloserine 125mg capsules Delamanid 25mg tablets or dispersible tablets

TB Medicines (New Formulation) for Which Suppliers are Required

Product Type	INN/strength/form
Adult DS-TB	3-FDC rifapentine 300mg/isoniazid 75mg/moxifloxacin 100mb tablets 4-FDC rifapentine 300mg/isoniazid 150mg/pyrazinamid 400mg/moxifloxacin 100mg tablets

December 2024



2024 GDF Tenders

Category of products	ITB number	Status	Contract duration
Ultraportable Digital X-Ray Kit, and Computer-Aided Detection using Artificial Intelligence (CAD/AI) software for Tuberculosis (TB)	RFP/2024/49478	Closed	31/07/2027
Delamanid 50mg tablets and 25mg dispersible	ITB-Iplus/GDF-MED/2024/1	Closed	31/12/2025
Interferon Gamma Release Assay (IGRA) for the detection of latent TB infection	ITB/2024/52841	Closed 03/09/2024	For 3 years
TB medicines (44 TB medicines)	ITB-Iplus/GDF-MED/2024/2	Closed	31/12/2025
Infection Prevention Supplies	RFP/2024/54109	Closed 02/12/2024	For 3 years
Bedaquiline 100mg et 20mg tablets, rifapentine /isoniazid 300mg/300mg tablets, rifapentine 300mg tablets and 150mg dispersible tablets	ITB-Iplus/GDF-MED/2024/3	Open Deadline 9/12/2024	31/12/2025

For TB medicines: <u>https://www.stoptb.org/what-we-do/facilitate-access-tb-drugs-diagnostics/global-drug-facility-gdf/suppliers/procurement-notices</u> For diagnostics: <u>https://www.ungm.org/Public/Notice</u>





Q1 2025 GDF Tenders

Category of products	Timelines
General laboratory supplies (around 230 items)*	Q1 2025
Pretomanid 200mg tablets**	Q1 2025

If you are a supplier of TB products that meet GDF's quality standards, deliver on time, and offer competitive and sustainable prices, please participate in GDF tenders.

If selected, you will be included in the **GDF catalog** and gain access to the **global TB market** to support us in the fight against TB, the **top infectious killer disease**.

* For diagnostics: <u>https://www.ungm.org/Public/Notice</u>. Contract for 3 years with an option to renew the LTA for two additional periods of one (1) year each, under the same terms and conditions for a maximum total of five (5) years

** For TB medicines: <u>https://www.stoptb.org/what-we-do/facilitate-access-tb-drugs-diagnostics/global-drug-facility-gdf/suppliers/procurement-</u> <u>notices</u> Contract with Initial term of 1 year with possibility of extension up to 12 months at a time under the same terms and conditions. Total duration of the Initial Term and all Extended Terms cannot exceed three years.





Summary – Take Home Points

- GDF is the largest supplier of affordable, quality-assured TB products to countries (165 countries served since its inception in 2001).
- GDF added value is the End-to-end approach along entire product lifecycle, coordinating TB market stakeholders.
- GDF expansion into medicines for AMR area could have significant impact.
- Partnership approach between GDF and suppliers is the approach of choice for access to TB products
- Suppliers interested to develop TB medicines are invited to contact GDF
- Suppliers of TB products that meet GDF's quality standards are invited to participate in GDF tenders



Thank You

Dr Magali Babaley <u>magalib@stoptb.org</u>

Acknowledgements:

Kaspars Lunte Bibiana Angarita Nigor Muzafarova Wilberforce Kwiringira Brenda Waning



-

